SALT LAKE CITY, March 25, 2014 /PRNewswire/ -- DiscGenics, Inc. (DiscGenics) announced today that its initial patent has been granted in four key international markets including Europe, Japan, China, and Israel. The issuance of this patent abroad extends the protection of the company's domestic intellectual property (IP) into major international markets. The European patent has also been validated in the key strategic European countries. Additional applications in other key global markets are pending to ensure broad coverage of DiscGenics' IP.
"A strong IP portfolio, both in the US and internationally, is a key component in DiscGenics' overall strategy," said CEO, Flagg Flanagan. "The granting of these patents secures the international foundation of our IP, which is being fortified with two additional domestic patent applications pending and more in process.”
About DiscGenics, Inc.
DiscGenics is a privately funded biotechnology company developing advanced spinal therapeutics to treat patients with diseases of the intervertebral disc. We are currently developing IDCT, a novel off-the-shelf injectable therapeutic based on regenerative medicine and progenitor cell science to treat pain associated with degenerative disc disease. News and other information on the company are available at: http:// www.DiscGenics.com.
Flagg Flanagan, Chief Executive Officer